Flt3 ligand induces monocyte proliferation and enhances the function of monocyte-derived dendritic cells in vitro

Journal of Cellular Physiology

Volumn 230, Issue 8, 2015, Pages 1740-1749

  Kim, Sung Whan ^a,b   Choi, Seong Mi ^b   Choo, Yee Shin ^c   Kim, Il Kwon ^a,b   Song, Byeong Wook ^a,b   Kim, Han Soo ^a,b  

^a Catholic Kwandong University   (South Korea)

^b International St Mary's Hospital   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 4; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; FLT3 LIGAND PROTEIN; MEMBRANE PROTEIN;

ARTICLE; CELL DEATH; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MONOCYTE; MONOCYTE DERIVED DENDRITIC CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; UPREGULATION; APOPTOSIS; CYTOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IN VITRO TECHNIQUES; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MONOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84928404438     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24824     Document Type: Article

References (49)

1. Akdis CA, Blaser K. 2001. Mechanisms of interleukin-10-mediated immune suppression. Immunol 103:131-136.
2. Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G, Schuler-Thurner B. 2002. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods 268:131-140.
3. Bhattacharyya S, Sen P, Wallet M, Long B, Baldwin ASJ, Tisch R. 2004. Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkB kinase activity. Blood 104:1100-1109.
4. Bohnenkamp HR, Burchell JM, Taylor-Papadimitriou J, Noll T. 2004. Apoptosis of monocytes and the influence on yielld of monocyte-derived dendritic cells. J Immunol Methods 294:67-80.
5. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Williams DE, Lyman SD. 1996. Hematologic effects of flt3 ligand in vivo in mice. Blood 88:2004-2012.
6. Brossart P, Zobywalski A, Grunebach F, Behnke L, Stuhler G, Reichardt VL, Kanz L, Brugger W. 2000. Tumor necrosis factor a and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res 60:4485-4492.
7. Broxmeyer HE, Lu L, Cooper S, Ruggieri L, Li ZH, Lyman SD. 1995. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 23:1121-1129.
8. Cano E, Mahadevan LC. 1995. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 20:117-122.
9. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. 1992. GM-CSF and TNF-a cooperate in the generation of dendritic Langerhans cells. Nature 360:258-261.
10. Cheung DL, Hamilton JA. 1992. Regulation of human monocyte DNA synthesis by colony-stimulating factors, cytokines, and cyclic adenosine monophosphate. Blood 79:1972-1981.
11. Clanchy FI, Holloway AC, Lari R, Cameron PU, Hamilton JA. 2006. Detection and properties of the human proliferative monocyte subpopulation. J Leukoc Biol 79:757-766.
12. DaSilva N, Hu Z, Ma W, Rosnet O, Birnbaum D, Drexler H. 1994. Expression of the FLT3 gene in human leukemia-lymphoma cell lines. Leukemia 8:885-888.
13. Fahy RJ, Doseff AI, Wewers MD. 1999. Spontaneous human monocyte apoptosis utilizes a caspase-3-dependent pathway that us blocked by endotoxin and is independent of caspase-1. J Immunol 163:1755-1762.
14. Finnin M, Hamilton JA, Moss ST. 1999. Characterization of a CSF-induced proliferating subpopulation of human peripheral blood monocytes by surface marker expression and cytokine production. J Leuk Biol 66:953-960.
15. Gabrilovich D. 2004. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Rev Immunol 4:941-952.
16. Harada S, Kimura T, Fujiki H, Nakagawa H, Ueda Y, Itoh T, Tamagishi H, Sonoda Y. 2007. Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: Possible application for cancer immunotherapy. Int J Oncol 30:1461-1468.
17. Hubert P, Greimers R, Franzen-Detrooz E, Doyen J, Delanaye P, Boniver J, Delvenne P. 1998. In vitro propagated dendritic cells from patients with human-papilloma virus-associated preneoplastic lesions of the uterine cervix: Use of flt3 ligand. Cancer Immunol Immunother 47:81-89.
18. Jonsson M, Engstrom M, Jonsson J-J. 2004. FLT3 ligand regulates apoptosis through AKT-dependent inactivation of transcription factor FoxO3. Biochem Biophys Res Comm 318:899-903.
19. Juan TS, McNiece IK, Van G Lacey, Hartley CJ, McElroy P, Sun Y, Argento J, Hill D, Yan XQ, Fletcher FA. 1997. Chronic expression of murine flt3 ligand in mice results in increased circulating white blood cell levels and abnormal cellular infiltrates associated with splenic fibrosis. Blood 90:76-84.
20. Kim HJ, Kim H-O, Baek EJ, Lee K, Kim H-S. 2010a. Two-step maturation of immature DCs with proinflammatory cytokine cocktail and poly(I:C) enhances migratory and allostimulatory capacity with high IL-12 production. Vaccine 28:2877-2886.
21. Kim HJ, Kim HO, Lee K, Baek EJ, Kim HS. 2010b. Two-step maturation of immature DCs with proinflammatory cytokine cocktail and poly(I:C) enhances migratory and T cell stimulatory capacity. Vaccine 28:2877-2886.
22. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K. 1995. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechansim for evading the local T cell immune response. J Immunol 155:2240-2247.
23. Langstein J, Michel J, Schwarz H. 1999. CD137 induces proliferation and endomitosis in monocytes. Blood 94:3161-3168.
24. Lee YJ, Koh YS, Park HE, Lee HJ, Hwang BH, Kang MK, Lee SY, Kim PJ, Ihm SH, Seung KB, Chang K. 2013. Spatial and temporal expression, and statin responsiveness of galectin-1 and galectin-3 in murine atherosclerosis. Korean Circ J 43:223-230.
25. Lewis JL, Marley SB, Ojo M, Gordon MY. 2004. Opposing effects of PI3 kinase pathway inactivation on human myeloid and erythroid progenitor cell proliferation and differentiation in vitro. Exp Hematol 32:36-44.
26. Li Q, Verma IM. 2002. NF-kB regulation in the immune system. Nature Rev Immunol 2:725-734.
27. Lyman SD, James L, Vander Bos, de Vries T, Brasel P, Gliniak K, Hollingsworth B, Picha LT, McKenna KS, Splett HJ, Fletcher RR, Maraskovsky FA, Farrah E, Foxworthe T, Williams D, Beckmann DE. 1993. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: A proliferative factor for primmitive hematopoietic cells. Cell 75:1157-1167.
28. Matsumura N, Mandai M, Hamanishi J, Yamaguchi K, Fukuhara K, Yagi H, Higuchi T, Takakura K, Fujii S. 2008. Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: Utilization for ovarian cancer treatment. Oncol Rep 19:505-515.
29. McNiece IK, Langley KE, Zsebo KM. 1991. Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 19:226-231.
30. Meierhoff G, Dehmel U, Gruss H-J, Rosnet O, Birnbaum D, Quentmeier H, Dirks W, Drexler HG. 1995. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia 9:1368-1372.
31. Meyer C, Drexler HG. 1999. FLT3 ligand inhibits apoptosis and promotes survival of myeloid leukemic cell lines. Leuk Lymphoma 32:577-581.
32. Palucka K, Banchereau J. 2013. Dendritic-cell-based therapeutic cancer vaccines. Immunity 39:38-48.
33. Pearson G, Robinson F, Beers Gibson, Xu T, Karandikar B-E, Berman M, Cobb K. 2001. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocine Rev 22:153-183.
34. Pulendran B, Banchereau J, Burkeholder S, Kraus E, Guinet E, Chalouni C, Caron D, Maliszewski C, Davoust J, Fay J, Palucka K. 2000. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 165:566-572.
35. Rappold I, Ziegler BL, Kohler I, Marchetto S, Rosnet O, Birnbaum D, Simmons PJ, Zannettino ACW, Hill B, Neu S, Knapp W, Alitalo R, Alitalo K, Ullrich A, Kanz L, Buhring H-J. 1997. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood 90:111-125.
36. Rosnet O, Schiff C, Pebusque MJ, Marchetto S, Tonnelle C, Toiron Y, Birg F, Birnbaum D. 1993. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 82:1110-1119.
37. Sekar D, Brune B, Weigert A. 2010. Technical advance: Generation of human pDC equivalents from primary monocytes using Flt3-L and their functional validation under hypoxia. J Leukoc Biol 88:413-424.
38. Shin J-W, Lee D-W, Kim M-J, Song K-S, Kim H-S, Kim H-O. 2005. Isolation of endothelial progenitor cells from cord blood and induction of differentiation by ex vivo expansion. Yonsei Med J 46:260-267.
39. Shurin MR, Esche C, Lotze MT. 1998. FLT3: receptor and ligand. Biology and potential clinical application.. Cytokine Growth Factor Rev 9:37-48.
40. Song SY, Kim H-S. 2004. Strategies to improve dendritic cell-based immunotherapy against cancer. Yonsei Med J 45:48-52.
41. Srinivasa SP, Doshi PD. 2002. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia 16:244-253.
42. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. 1997. Induction of tolerance by IL-10 treated dendritic cells. J Immunol 159:4772-4780.
43. Steinman RM, Dhodapkar M. 2001. Active immunization against cancer with dendritic cells: The near future. Int J Cancer 94:459-473.
44. van Rooijen N. 1990. Antigen processing and presentation in vivo: the microenvironment as a crucial factor. Immunol Today 11:436-439.
45. Weisel KC, Yildirim S, Scgweikle E, Kanz L, Mohle R. 2007. Effect of flt3 inhibition on normal hematopoietic progenitor cells.. Ann NY Acad Sci 1106:190-196.
46. Zeigler FC, Bennet BD, Jordan CT, Spencer SD, Baumhueter S, Carroll KJ, Hooley J, Bauer K, Matthews W. 1994. Cellular and molecular characterization of the role of the FLK-2/FLT3 receptor tyrosine kinase in hematopoietic stem cells. Blood 84:2422-2430.
47. Zhang S, Mantel C, Broxmeyer HE. 1999. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J Leukoce Biol 65:372-380.
48. Zhou L-J, Tedder TF. 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 154:3821-3835.
49. + dendritic cells. Proc Natl Acad Sci USA 93:2588-2592.